Trade Summary

3 months ago, Arch Venture Partners Ix, LLC, serving as 10% owner at Lyell Immunopharma, Inc. (LYEL), purchased 488,090 shares at $25.61 per share, for a total transaction value of $12,499,985.00. Following this transaction, Arch Venture Partners Ix, LLC now holds 3,247,162 shares of LYEL.

This purchase represents a 18.00% increase in Arch Venture Partners Ix, LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, March 6, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 9, 2026 at 4:36 PM ET, 3 days after the trade was made.

Lyell Immunopharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.